- Home
- AKBA vs FCRS Comparison
AKBA vs FCRS Comparison
Compare AKBA & FCRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AKBA | FCRS |
|---|---|---|
| Founded | 2007 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.0M | 362.3M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | AKBA | FCRS |
|---|---|---|
| Price | $1.43 | $10.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.25 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 63.9K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $10.02 |
| 52 Week High | $4.08 | $10.92 |
Technical Indicators
Market Signals| Indicator | AKBA | FCRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 61.79 |
| Support Level | $1.30 | $10.08 |
| Resistance Level | $1.55 | $10.19 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 42.37 | 71.43 |
Price Performance
Historical ComparisonAbout AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
About FCRS FutureCrest Acquisition Corp. Class A Ordinary Shares
FutureCrest Acquisition Corp is a blank check company.